CanSino Biologics Inc. (6185.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Xue Feng Yu
Listed since: Mar 28, 2019
Employees: 1,134

Market position

Day range

Current HK$27.18

HK$27.14HK$30.68

52-week range

Current HK$27.18

HK$19.22HK$56.55

Open: HK$30.50
Previous close: HK$29.48
Volume: 9.73M; 6.02× average
Average volume: 1.62M; Average daily volume
Market cap: 9.52B HKD
Beta: 1.22; Market reference 1
50-day average: HK$23.6944; +14.71% above average
200-day average: HK$31.627; -14.06% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 8B CNY
P/E (TTM): 2,537.58×
P/B (TTM): 3.79×
P/S (TTM): 12.32×
EV / EBITDA: 131.2×
Earnings yield: 0.34%
Free cash flow yield: -1.92%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 75.00%
Operating margin: -0.16%
Net margin: -0.09%
Return on equity: 0.55%
Return on assets: 0.38%
Return on invested capital: -1.76%

Financial health

Debt / equity: 0.24×
Current ratio: 3.55×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

1.03B CNY+21.93%

Operating income

−113.12M CNY+69.85%

Net income

27.15M CNY+406.04M CNY

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.03B CNY	846.34M CNY	345.18M CNY	1.03B CNY	4.3B CNY
Cost of goods sold	350.15M CNY	244.43M CNY	1.22B CNY	1.22B CNY	1.3B CNY
Gross profit	681.82M CNY	601.91M CNY	−876.02M CNY	−186.61M CNY	3B CNY
Research and development	230.47M CNY	416.12M CNY	637.99M CNY	778.26M CNY	878.72M CNY
Selling, general, and administrative	589.83M CNY	563.41M CNY	647.85M CNY	544.68M CNY	337.63M CNY
Operating expenses	794.94M CNY	958.8M CNY	1.16B CNY	1.18B CNY	1.2B CNY
Interest income	68.5M CNY	63.87M CNY	100.06M CNY	65.93M CNY	79.65M CNY
Interest expense	55.81M CNY	59.98M CNY	64.15M CNY	41.34M CNY	20.42M CNY
Depreciation and amortization	174.1M CNY	240.39M CNY	269.05M CNY	180.13M CNY	65.11M CNY
Operating income	−113.12M CNY	−375.22M CNY	−2.04B CNY	−1.37B CNY	1.94B CNY
Net income	27.15M CNY	−378.88M CNY	−1.48B CNY	−909.43M CNY	1.91B CNY